Medicare AdvantageDocumentationMedium impact
MA08.024m, Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®)
Independence Blue Cross·Pulmonology, Allergy & Immunology, Internal Medicine +1 more·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.024m updates medical necessity criteria, medical coding guidelines, and general informational content for IL-5 antagonist and IL-5 receptor antagonist medications (Cinqair®, Nucala®, Fasenra®). This recent change (effective 03/24/2025) requires billing and clinical teams to align documentation, coding practices, and prior authorization submissions with new medical necessity standards for these biologics used in asthma and eosinophilic conditions.
Action Required
By 03/24/2025: Billing team must review MA08.024m policy updates and implement new medical necessity criteria for IL-5 antagonist claims (Cinqair®, Nucala®) and IL-5 receptor antagonist claims (Fasenra®). Coordinate with providers and clinical staff to ensure all prior authorization requests include updated documentation supporting medical necessity per new guidelines. Update claim submission processes to reflect any coding changes outlined in the policy. Verify that encounter documentation templates capture required clinical criteria. Review any existing denials from this medication class and resubmit if documentation now meets updated criteria. Failure to align with new medical necessity standards will result in claim denials on Medicare Advantage plans.